Healthcare Industry News: Siemens Healthcare
News Release - September 17, 2008
BioImagene Appoints Dr. Ajit Singh as CEOFounder and Current CEO Mohan Uttarwar to Take on the Role of Chief Strategy Officer
CUPERTINO, Calif.--(HSMN NewsFeed)--BioImagene, the leading provider of innovative and affordable digital pathology solutions for cancer diagnosis and pre clinical research, today announced the appointment of Ajit Singh, Ph.D. as Chief Executive Officer (CEO). Dr. Singh had joined the Board of Directors of the company in July 2008, prior to the closing of the $26M expansion financing round. He will assume the CEO role starting October 6th, 2008.
The founder and the current CEO, Mohan Uttarwar will remain with the company, serve on the Board of Directors, and take on the role of Chief Strategy Officer.
Mr. G. Steven Burrill, Chairman of the Board of BioImagene, said, “We are delighted to have Ajit at the helm of BioImagene. The company has established itself as a clear innovation leader in Digital Pathology over the past years, and is well positioned to lead the market. Ajit brings with him tremendous experience in the area of Oncology, Medical Imaging, Healthcare Information Systems, and Knowledge Based Medicine. Digital Pathology sits exactly at the nexus of these fields.”
Dr. Singh’s most recent position was as the CEO of the Image and Knowledge Management business of Siemens Healthcare, based in Germany. He has spent nearly twenty years at Siemens in various roles. Prior to taking on his current responsibility in 2006, he was the CEO of the Oncology Care Systems business of Siemens for five years, based in California. He has a Ph.D. in Computer Science from Columbia University.
“We are very fortunate to have the insight and experience that Ajit brings to the table,” said Mohan Uttarwar, founder and CEO, BioImagene. “I look forward to working closely with him to help BioImagene achieve a dominant position in digital pathology,” he added.
Dr. Ajit Singh said, “I am excited about joining BioImagene. The company has led the way in innovation – both in technology and in business models. It is time to stimulate a widespread adoption of Digital Pathology. I view this as an ‘industry shaping’ exercise.”
Mr. Yatin Mundkur, a partner at Artiman Ventures, one of the early investors in BioImagene, commented, “We are proud of what BioImagene has achieved in such a short time under the leadership of Mohan Uttarwar. With innovations in biomarker discovery and imaging, digital pathology is at the threshold of going mainstream. Having known Ajit for many years, I am thrilled that we have him on the team as we enter this next phase of growth.”
BioImagene is a leading provider of total digital pathology solutions for applications including clinical diagnostics and drug discovery. BioImagene products are FDA -cleared for specific clinical applications, and are intended for research use for other applications. www.bioimagene.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.